Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Exp Immunol ; 184(2): 216-27, 2016 May.
Article in English | MEDLINE | ID: mdl-26621323

ABSTRACT

Chronic mucocutaneous candidiasis (CMC) is characterized by recurrent and persistent superficial infections, with Candida albicans affecting the mucous membranes, skin and nails. It can be acquired or caused by primary immune deficiencies, particularly those that impair interleukin (IL)-17 and IL-22 immunity. We describe a single kindred with CMC and the identification of a STAT1 GOF mutation by whole exome sequencing (WES). We show how detailed clinical and immunological phenotyping of this family in the context of WES has enabled revision of disease status and clinical management. Together with analysis of other CMC cases within our cohort of patients, we used knowledge arising from the characterization of this family to develop a rapid ex-vivo screening assay for the detection of T helper type 17 (Th17) deficiency better suited to the routine diagnostic setting than established in-vitro techniques, such as intracellular cytokine staining and enzyme-linked immunosorbent assay (ELISA) using cell culture supernatants. We demonstrate that cell surface staining of unstimulated whole blood for CCR6⁺ CXCR3⁻ CCR4⁺ CD161⁺ T helper cells generates results that correlate with intracellular cytokine staining for IL-17A, and is able to discriminate between patients with molecularly defined CMC and healthy controls with 100% sensitivity and specificity within the cohort tested. Furthermore, removal of CCR4 and CD161 from the antibody staining panel did not affect assay performance, suggesting that the enumeration of CCR6⁺ CXCR3⁻ CD4⁺ T cells is sufficient for screening for Th17 deficiency in patients with CMC and could be used to guide further investigation aimed at identifying the underlying molecular cause.


Subject(s)
Candida albicans/immunology , Candidiasis, Chronic Mucocutaneous/diagnosis , Candidiasis, Chronic Mucocutaneous/genetics , STAT1 Transcription Factor/genetics , Th17 Cells/immunology , Adolescent , Adult , Base Sequence , CD4 Antigens/metabolism , Candidiasis, Chronic Mucocutaneous/microbiology , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Exome/genetics , Family , Female , Humans , Infant , Interleukin-17/immunology , Male , Middle Aged , Mucous Membrane/immunology , Mucous Membrane/microbiology , Receptors, CCR6/metabolism , Receptors, CXCR3/metabolism , Sequence Analysis, DNA , Staining and Labeling , Young Adult
2.
Clin Exp Immunol ; 165(1): 1-7, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21470209

ABSTRACT

Common variable immunodeficiency disorders (CVIDs) are the most frequent symptomatic primary immunodeficiencies in adults. They comprise a heterogeneous group of pathologies, with frequent non-infectious complications in addition to the bacterial infections that usually characterize their presentation. Complications include a high risk of malignancy, especially lymphoma and gastric cancer. Helicobacter pylori infection and pernicious anaemia are risk predictors for gastric cancer in the general population and probably in patients with CVIDs. Screening for gastric cancer in a high-risk population appears to improve survival. Given the increased risk of gastric cancer in patients with CVIDs and prompted by a case of advanced gastric malignancy in a patient with a CVID and concomitant pernicious anaemia, we performed a review of the literature for gastric cancer and conducted a cohort study of gastric pathology in 116 patients with CVIDs under long-term follow-up in Oxford. Regardless of the presence of pernicious anaemia or H. pylori infection, patients with CVIDs have a 10-fold increased risk of gastric cancer and are therefore a high-risk population. Although endoscopic screening of all patients with CVIDs could be considered, a more selective approach is appropriate and we propose a surveillance protocol that should reduce modifiable risk factors such as H. pylori, in order to improve the management of patients with CVIDs at risk of gastric malignancy.


Subject(s)
Common Variable Immunodeficiency/epidemiology , SEER Program , Stomach Neoplasms/epidemiology , Anemia, Pernicious , Bacterial Infections , Common Variable Immunodeficiency/diagnosis , Common Variable Immunodeficiency/immunology , Common Variable Immunodeficiency/physiopathology , Early Detection of Cancer/standards , Humans , Practice Guidelines as Topic , Risk Factors , Stomach Neoplasms/diagnosis , Stomach Neoplasms/immunology , Stomach Neoplasms/physiopathology , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL